X4 Pharmaceuticals, Inc
XFORNasdaqCIK 1501697HealthcareFiscal year ends Dec 31
Reports and events: 214 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-0817:23 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001501697-26-000081 |
| 2026-09-0917:36 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001501697-26-000076 |
| 2026-09-0807:15 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001501697-26-000072 |
| 2026-08-0616:08 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001501697-26-000068 |
| 2026-07-0116:13 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001501697-26-000060 |
| 2026-05-1316:57 ET | 8-K/A | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001501697-26-000051 |
| 2026-05-1216:21 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001501697-26-000047 |
| 2026-05-0607:01 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001501697-26-000040 |
| 2026-03-2008:45 ET | DEF 14A | Proxy statementPeriod 2026-03-20 | 0001501697-26-000031 |
| 2026-03-1706:59 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001501697-26-000018 |
| 2025-11-0508:25 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001501697-25-000043 |
| 2025-11-0508:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001501697-25-000041 |
| 2025-10-2918:04 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001072613-25-000747 |
| 2025-10-2718:47 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001501697-25-000032 |
| 2025-09-1707:03 ET | 8-K | 2.05 Exit or disposal costs; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001501697-25-000021 |
| 2025-08-2508:12 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001501697-25-000008 |
| 2025-08-1816:26 ET | SCHEDULE 13D | Ownership report, active investor | 0001104659-25-079821 |
| 2025-08-1516:54 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001072613-25-000643 |
| 2025-08-1321:40 ET | SCHEDULE 13D | Ownership report, active investor | 0000950170-25-108341 |
| 2025-08-1308:13 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001501697-25-000006 |
| 2025-08-1208:25 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-25-039770 |
| 2025-08-0817:03 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001628280-25-039327 |
| 2025-06-2316:34 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001628280-25-032627 |
| 2025-06-1116:17 ET | 8-K | 5.07 Shareholder vote results | 0001628280-25-030743 |
| 2025-05-0109:22 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001628280-25-021358 |
| 2025-05-0106:25 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure | 0001628280-25-021304 |
| 2025-04-2516:44 ET | DEF 14A | Proxy statementPeriod 2025-04-25 | 0001628280-25-019926 |
| 2025-04-2408:57 ET | 8-K | 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-25-019507 |
| 2025-04-1816:18 ET | 8-K | 5.07 Shareholder vote results | 0001628280-25-018389 |
| 2025-03-2618:16 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001628280-25-014805 |
| 2025-03-2507:51 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-25-014601 |
| 2025-03-2416:43 ET | DEF 14A | Proxy statementPeriod 2025-03-24 | 0001628280-25-014535 |
| 2025-03-0317:02 ET | 8-K | 8.01 Other events | 0001628280-25-009490 |
| 2025-02-0616:06 ET | 8-K | 2.05 Exit or disposal costs; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-25-004254 |
| 2025-01-1307:50 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-25-001239 |
| 2024-11-1309:02 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001628280-24-047445 |
| 2024-11-1308:11 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-24-047433 |
| 2024-11-1306:12 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-24-047406 |
| 2024-08-1616:03 ET | 8-K | 3.01 Delisting notice | 0001628280-24-037546 |
| 2024-08-0916:28 ET | 8-K | 7.01 Regulation FD disclosure | 0001628280-24-036495 |
| 2024-08-0816:08 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001628280-24-036127 |
| 2024-08-0806:40 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-24-035848 |
| 2024-07-1908:17 ET | 8-K | 7.01 Regulation FD disclosure | 0001628280-24-032266 |
| 2024-06-2708:01 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-24-030243 |
| 2024-06-1116:14 ET | 8-K | 5.07 Shareholder vote results | 0001628280-24-027680 |
| 2024-05-2208:09 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-24-024633 |
| 2024-05-0906:58 ET | 8-K | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-24-021937 |
| 2024-05-0716:23 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001628280-24-021120 |
| 2024-05-0706:28 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-24-020827 |
| 2024-04-2916:54 ET | DEF 14A | Proxy statementPeriod 2024-04-29 | 0001628280-24-019056 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 29, 2026, 10:01 ET. Listed shows no prices and gives no investment advice.